Infusion of a novel peptide, PHI, in man. Pharmacokinetics and effect on gastric secretion.
PHI, infused in man, achieved plateau plasma levels of 297 pmoles/1. The plasma half life was 3.1 min, metabolic clearance rate was 16.4 ml/kg/min and estimated volume of distribution was 73.2 ml/kg. No subjective side effects were noted during the infusion and there was no significant alteration in submaximal pentagastrin stimulated gastric acid or pepsin secretion.
D000328:Adult; D005744:Gastric Acid / Q000378:metabolism*; D006801:Humans; D007700:Kinetics; D008297:Male; D010418:Pentagastrin / Q000494:pharmacology; D010434:Pepsin A / Q000378:metabolism*; D010451:Peptide PHI; D010455:Peptides / Q000378:metabolism*; D013997:Time Factors
D010451:Peptide PHI; D010455:Peptides; D010434:Pepsin A; D010418:Pentagastrin